Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Go back to Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) Delayed: 59.11 --0 (-0%)
Previous Close $59.11    52 Week High $35.13 
Open $59.11    52 Week Low $28.10 
Day High $59.49    P/E N/A 
Day Low $58.83    EPS $0.00 
Volume 1,311,205